Keep Factually independent
Whether you agree or disagree with our analysis, these conversations matter for democracy. We don't take money from political groups - even a $5 donation helps us keep it that way.
What side effects are typical after mRNA COVID-19 vaccines like Pfizer and Moderna?
Executive summary
mRNA COVID-19 vaccines (Pfizer-BioNTech BNT162b2 and Moderna mRNA‑1273) commonly cause short-lived local and systemic reactions — injection‑site pain, fatigue, headache, muscle and joint aches, and fever — that are more frequent after the second dose and typically resolve in a few days [1] [2] [3]. Rare but serious events—most notably myocarditis/pericarditis in younger males and a small excess of other serious adverse events in trial meta‑analysis—have been identified and quantified in several studies (myocarditis risk concentrated in young males after dose two; excess serious adverse events ≈12.5 per 10,000 in pooled trial analysis) [4] [5] [6].
1. What reactions are typical and how long do they last?
Large clinical trials and surveillance systems show the typical profile: local reactions at the injection site and systemic symptoms such as fatigue, headache, muscle pain, joint pain and fever. These are usually transient and peak the day after vaccination, subsiding by about day 3–4; reactogenicity is generally stronger after the second dose and more pronounced with Moderna than Pfizer in several cohort studies [3] [1] [7].
2. How common are the “severe” but non‑permanent reactions?
Interim trial analyses defined “severe” as reactions preventing daily activities. In Moderna’s trial, severe fatigue (9.7%), muscle pain (8.9%), joint pain (5.2%) and headache (4.5%) were reported; Pfizer’s trial showed lower percentages for severe events (severe fatigue 3.8%, headache 2%) [1]. Real‑world surveys often find 60–90% of recipients report at least one side effect after a dose, with most symptoms short‑lived [8] [9].
3. Rare but serious risks identified — what do the data say?
Post‑licensure and pooled analyses have identified rare serious events. Myocarditis and pericarditis after mRNA vaccines—most commonly in male adolescents and young adults and often after the second dose—are confirmed safety signals; reported rates vary by age and sex but can be tens of cases per million doses in the highest‑risk groups [4] [6]. A pooled secondary analysis of Pfizer and Moderna randomized trials found an excess of serious adverse events of special interest of about 12.5 per 10,000 vaccinated (95% CI 2.1 to 22.9) compared with placebo, with the Pfizer trial showing a larger relative excess than Moderna in that analysis [5].
4. What about cardiovascular and other system‑specific events?
Systematic reviews and surveillance capture a range of cardiovascular events reported after vaccination (palpitations, tachycardia, chest pain, rare myocarditis). Studies categorize some cardiovascular adverse events as severe and note differences between vaccines (some signal differences in frequency/severity between Pfizer and Moderna in observational series), but the absolute numbers remain small compared with doses administered [10] [11] [6].
5. How do regulators and public‑health bodies interpret these risks?
Regulatory and public‑health authorities have weighed the rare risks against the benefits of vaccination. CDC analyses found higher rates of Guillain‑Barré syndrome after Janssen (J&J) but not after mRNA vaccines, and recommended preferential use of mRNA vaccines over J&J in that context [12]. Independent large studies have largely confirmed known rare vaccine side effects and emphasized their rarity relative to COVID‑19 risks [4].
6. What are the main disagreements, limitations and open questions?
Studies differ in methods (trial vs. passive surveillance, cohort vs. case‑control), resulting in variability in absolute risk estimates and which rare events are flagged. The Global Vaccine Data Network study flagged very rare neurological events and reinforced myocarditis/pericarditis signals, but also found some associations limited to particular vaccine doses or types; other analyses report no association of mRNA vaccines with certain rare events [6]. A pooled trial reanalysis reported an excess of serious events [5] whereas larger post‑marketing surveillance frames those rare outcomes as uncommon and generally manageable; differences reflect study design, follow‑up duration and outcome definitions [5] [6].
7. Practical takeaways for people considering vaccination
Expect local soreness and systemic symptoms like fatigue, headache, muscle aches and sometimes fever, especially after dose two, resolving within a few days [3] [1]. Healthcare systems monitor for very rare but serious events (myocarditis, pericarditis and select neurologic or cardiac signals); these risks are small in absolute terms but have been quantified in targeted studies and surveillance [4] [6] [5]. If you have a history of severe allergic reaction, discuss it with a clinician because anaphylaxis was documented early in rollout and is managed in healthcare settings [11].
Limitations: available sources do not mention long‑term effects beyond what post‑marketing surveillance and the cited studies report; absolute risk estimates vary across datasets and age/sex subgroups, so individual risk depends on age, sex, medical history and exposure to COVID‑19 [5] [6].